Tiziana Announces Plans for Clinical Development of Foralumab, the Com


Sign up online today & collaborate

or click here to find out more

Tiziana Announces Plans for Clinical Development of Foralumab, the Company’s Fully Human CD3 Antibody


Tiziana adds Profs Kevan Herold and Howard Weiner to Scientific Advisory Board, providing key leadership and experience in CD3 clinical development

11 January 2016: London, UK – Tiziana Life Sciences plc (AIM: TILS, the “Company”), a clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, today announced its plan for further development of foralumab, the company’s fully human anti-CD3 antibody, along with the addition of two key members: Professors Kevan Herold, MD and Howard Weiner, MD who will be joining its Scientific Advisory Board and focusing on pioneering a unique  clinical development plan for foralumab.  The company will first be evaluating foralumab in two clinical indications: 1) graft vs host disease, and 2) ulcerative colitis, an inflammatory bowel disease.

“The addition of Professors Herold and Weiner to Tiziana’s Scientific Advisory Board marks a vital step for the company,” said Gabriele Cerrone, Executive Chairman. “Prof. Herold’s previous experience in CD3 antibody research will be invaluable in planning the clinical strategy for foralumab, and he will take on a major role in its further development.  In addition, Prof. Weiner brings a wealth of expertise in the field of immunology and regulation of processes that govern cancer and autoimmune disease, which will also be critical as we build out our anti-CD3 clinical strategy and the development of our fully human antibody asset, foralumab.”

Dr. Kevan Herold is Professor of Immunobiology and of Medicine (Endocrinology) as well as Deputy Director, Yale Center for Clinical Investigation, Director of the Yale Diabetes Center and Director of the TrialNet Center at Yale. His investigative work has focused on developing new ways to prevent and treat autoimmune diseases, using novel translational immunologic and metabolic approaches to prevent progression, in particular anti-CD3 monoclonal antibody therapy. His clinical interests are in the management of endocrine diseases, and he is involved in a number of national and international clinical studies of new treatments.

Dr. Howard Weiner is the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director and Founder of the Partners Multiple Sclerosis (MS) Center and Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham & Women’s Hospital in Boston. The Partners MS Center is the first integrated MS Center that combines clinical care, MRI imaging and immune monitoring to the MS patient as part of the 2000 patient CLIMB cohort study. He has pioneered immunotherapy in MS and has investigated immune mechanisms in nervous system diseases including MS, Alzheimer’s disease, amyotrophic lateral sclerosis, stroke and brain tumours. He has also pioneered the investigation of the mucosal immune system for the treatment of autoimmune and other diseases and the use of anti-CD3 to induce regulatory T cells for the treatment of these diseases.

Company Tiziana Life Sciences plc
Company Website


© Catalyst Innovation Portal 2019